Fig. 1From: PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomyBiochemical recurrence-free survival according to miTNM stage. Pairwise comparison: miTNM stage IA versus miTNM stage IB, p = 0.022; miTNM stage IA versus miTNM stage ≥ II, p = 0.001; miTNM stage IB versus miTNM stage ≥ II, p = 0.005Back to article page